1.05
price up icon10.50%   0.0998
pre-market  プレマーケット:  1.05  
loading
前日終値:
$0.9502
開ける:
$0.9502
24時間の取引高:
426.74K
Relative Volume:
0.08
時価総額:
$11.29M
収益:
-
当期純損益:
$-29.77M
株価収益率:
-0.0686
EPS:
-15.2954
ネットキャッシュフロー:
$-24.23M
1週間 パフォーマンス:
+23.67%
1か月 パフォーマンス:
-3.67%
6か月 パフォーマンス:
-58.82%
1年 パフォーマンス:
-75.58%
1日の値動き範囲:
Value
$0.9502
$1.0536
1週間の範囲:
Value
$0.82
$1.0536
52週間の値動き範囲:
Value
$0.3975
$5.47

Moleculin Biotech Inc Stock (MBRX) Company Profile

Name
名前
Moleculin Biotech Inc
Name
セクター
Healthcare (1153)
Name
電話
713-300-5160
Name
住所
5300 MEMORIAL DRIVE, HOUSTON, TX
Name
職員
17
Name
Twitter
@moleculinbio
Name
次回の収益日
2024-12-08
Name
最新のSEC提出書
Name
MBRX's Discussions on Twitter

MBRX を他の銘柄と比較する

株式 価格 時価総額 収益 当期純利益 現金流量 EPS
Biotechnology icon
MBRX
Moleculin Biotech Inc
1.05 11.29M 0 -29.77M -24.23M -15.30
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
490.47 128.67B 11.02B -535.60M -978.00M -2.20
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
585.49 60.99B 14.20B 4.41B 3.54B 38.28
Biotechnology icon
ARGX
Argen X Se Adr
599.87 36.96B 2.19B 833.04M -1.28B 12.71
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
236.75 29.89B 2.25B -278.16M -42.59M -2.17
Biotechnology icon
ONC
Beigene Ltd Adr
252.77 25.74B 3.81B -644.79M -669.77M -6.24

Moleculin Biotech Inc Stock (MBRX) Upgrades & Downgrades

日付 アクション アナリスト 評価の変更
2025-02-12 ダウングレード Maxim Group Buy → Hold
2022-07-18 再開されました Oppenheimer Outperform

Moleculin Biotech Inc (MBRX) 最新ニュース

pulisher
Apr 21, 2025

Moleculin Biotech Releases Corporate Presentation Online - TipRanks

Apr 21, 2025
pulisher
Apr 18, 2025

Moleculin Announces Pricing of $3.5 Million Registered Direct Offering and Concurrent Private Placement Priced At The Market Under Nasdaq Rules (PR Newswire) - Aktiellt

Apr 18, 2025
pulisher
Apr 17, 2025

Moleculin Biotech’s Annamycin Highlighted at AACR 2025 - TipRanks

Apr 17, 2025
pulisher
Apr 17, 2025

Moleculin Announces Acceptance of Abstract to be Presented at the American Association for Cancer Research (AACR) Annual Meeting 2025 | MBRX Stock News - GuruFocus

Apr 17, 2025
pulisher
Apr 17, 2025

Moleculin Announces Acceptance of Abstract to be Presented - GlobeNewswire

Apr 17, 2025
pulisher
Apr 17, 2025

Major Cancer Research Breakthrough: Moleculin's Annamycin Drug Combinations Study Heads to AACR 2025 - Stock Titan

Apr 17, 2025
pulisher
Apr 09, 2025

Moleculin Biotech adjourns special meeting due to lack of quorum By Investing.com - Investing.com South Africa

Apr 09, 2025
pulisher
Apr 09, 2025

Moleculin Biotech adjourns special meeting due to lack of quorum - Investing.com Australia

Apr 09, 2025
pulisher
Apr 07, 2025

Moleculin Reports Second Quarter 2023 Financial Results - Seeking Alpha

Apr 07, 2025
pulisher
Apr 02, 2025

Moleculin Biotech doses first patient in Phase 3 MIRACLE trial - Yahoo Finance

Apr 02, 2025
pulisher
Apr 02, 2025

Moleculin Biotech begins dosing subjects in trial of combination therapy for AML - Yahoo

Apr 02, 2025
pulisher
Apr 01, 2025

Moleculin Doses First Patient in Pivotal, Adaptive Phase 3 MIRACLE Trial - GlobeNewswire

Apr 01, 2025
pulisher
Apr 01, 2025

Here's Why Moleculin Biotech (MBRX) Is a Great 'Buy the Bottom' Stock Now - Yahoo Finance

Apr 01, 2025
pulisher
Apr 01, 2025

Moleculin Biotech Begins Phase 3 MIRACLE Trial Dosing - TipRanks

Apr 01, 2025
pulisher
Apr 01, 2025

Moleculin Doses First Patient In Pivotal, Adaptive Phase 3 Miracle Trial - MarketScreener

Apr 01, 2025
pulisher
Apr 01, 2025

Breakthrough AML Treatment Enters Final Testing Phase: Moleculin Launches Pivotal Trial - Stock Titan

Apr 01, 2025
pulisher
Mar 29, 2025

Moleculin, CNS, Global-e, Tenet, Summit: Trending by Analysts - MSN

Mar 29, 2025
pulisher
Mar 28, 2025

What is HC Wainwright’s Estimate for MBRX FY2025 Earnings? - Defense World

Mar 28, 2025
pulisher
Mar 27, 2025

Roth Capital Issues Optimistic Estimate for MBRX Earnings - Defense World

Mar 27, 2025
pulisher
Mar 26, 2025

All You Need to Know About Moleculin Biotech (MBRX) Rating Upgrade to Buy - MSN

Mar 26, 2025
pulisher
Mar 26, 2025

Moleculin Biotech (NASDAQ:MBRX) Rating Increased to Buy at Maxim Group - Defense World

Mar 26, 2025
pulisher
Mar 26, 2025

Maxim Group Upgrades Moleculin Biotech (MBRX) - MSN

Mar 26, 2025
pulisher
Mar 26, 2025

Moleculin Biotech (NASDAQ:MBRX) Upgraded at StockNews.com - Defense World

Mar 26, 2025
pulisher
Mar 26, 2025

Maxim Group Upgrades Moleculin Biotech (LSE:0K2H) - Nasdaq

Mar 26, 2025
pulisher
Mar 25, 2025

H.C. Wainwright maintains $8 target on Moleculin Biotech stock By Investing.com - Investing.com Australia

Mar 25, 2025
pulisher
Mar 25, 2025

H.C. Wainwright maintains $8 target on Moleculin Biotech stock - Investing.com

Mar 25, 2025
pulisher
Mar 25, 2025

Maxim Upgrades Moleculin Biotech to Buy From Hold, Price Target is $4 - Marketscreener.com

Mar 25, 2025
pulisher
Mar 25, 2025

Moleculin Biotech, Inc. (NASDAQ:MBRX) Q4 2024 Earnings Call Transcript - Insider Monkey

Mar 25, 2025
pulisher
Mar 25, 2025

Moleculin Biotech Inc (MBRX) Q4 2024 Earnings Call Highlights: Promising Clinical Trials and ... - Yahoo Finance

Mar 25, 2025
pulisher
Mar 25, 2025

Moleculin Biotech (NASDAQ:MBRX) Receives Buy Rating from HC Wainwright - Defense World

Mar 25, 2025
pulisher
Mar 25, 2025

Moleculin Biotech Inc (MBRX) Q4 2024 Earnings Call Highlights: P - GuruFocus

Mar 25, 2025
pulisher
Mar 24, 2025

Moleculin Biotech Advances Clinical Trials Amid Financial Losses - TipRanks

Mar 24, 2025
pulisher
Mar 24, 2025

Earnings call transcript: Moleculin Biotech’s Q1 2025 updates on Anamycin trials By Investing.com - Investing.com South Africa

Mar 24, 2025
pulisher
Mar 24, 2025

Earnings call transcript: Moleculin Biotech’s Q1 2025 updates on Anamycin trials - Investing.com

Mar 24, 2025
pulisher
Mar 24, 2025

Moleculin Biotech Inc Reports Q4 Earnings: EPS of -$1.28, Revenue at $0 Million, Aligns with Analyst Estimates - GuruFocus

Mar 24, 2025
pulisher
Mar 24, 2025

Moleculin Reports Full Year 2024 Financial Results and Provides Corporate Update - GlobeNewswire

Mar 24, 2025
pulisher
Mar 24, 2025

Moleculin Biotech Shares Corporate Presentation Update - TipRanks

Mar 24, 2025
pulisher
Mar 24, 2025

FDA-Optimized Phase 3 AML Trial: Moleculin Cuts Costs, Expands to Europe - Stock Titan

Mar 24, 2025
pulisher
Mar 21, 2025

Moleculin Biotech Inc reports results for the quarter ended December 31Earnings Summary - TradingView

Mar 21, 2025
pulisher
Mar 21, 2025

Moleculin Biotech, Inc. SEC 10-K Report - TradingView

Mar 21, 2025
pulisher
Mar 19, 2025

Moleculin to Report Full Year 2024 Financial Results on March 21, 2025 and Host Conference Call and Webcast - GlobeNewswire

Mar 19, 2025
pulisher
Mar 19, 2025

Moleculin Biotech Prepares to Unveil Critical 2024 Financial Performance - Stock Titan

Mar 19, 2025
pulisher
Mar 18, 2025

Moleculin Biotech Inc expected to post a loss of $1.28 a shareEarnings Preview - TradingView

Mar 18, 2025
pulisher
Mar 13, 2025

Moleculin Biotech (NASDAQ:MBRX) Now Covered by StockNews.com - Defense World

Mar 13, 2025
pulisher
Mar 11, 2025

Moleculin Biotech, Inc. Participates in the Virtual Investor "Top 5 for '25" On-Demand Conference - PR Newswire

Mar 11, 2025

Moleculin Biotech Inc (MBRX) 財務データ

収益

loading

当期純利益

loading

現金流量

loading

EPS

loading
$20.27
price up icon 1.00%
$71.24
price up icon 2.49%
$32.19
price up icon 0.00%
$27.35
price up icon 8.45%
$104.68
price up icon 2.82%
biotechnology ONC
$252.77
price up icon 10.27%
大文字化:     |  ボリューム (24 時間):